Innate Pharma S.A. ADS (IPHA) is a publicly traded Healthcare sector company. As of October 20, 2026, IPHA trades at $1.46 with a market cap of $159.73M and a P/E ratio of 0.00. IPHA moved +0.00% today. Year to date, IPHA is -16.57%; over the trailing twelve months it is -31.78%. Its 52-week range spans $1.17 to $2.71. Analyst consensus is strong buy with an average price target of $6.67. Rallies surfaces IPHA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
3 analysts cover IPHA: 0 strong buy, 3 buy, 0 hold, 0 sell, and 0 strong sell. The consensus rating is strong buy. The average price target is $6.67.
| Metric | Value |
|---|---|
| Price | $1.46 |
| Market Cap | $159.73M |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $2.71 |
| 52-Week Low | $1.17 |
| Volume | 8.13K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $0 |
| Gross Margin | 0.00% |
3 analysts cover IPHA: 0 strong buy, 3 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $6.67.